IBAB reports H1 2026 revenue and margin growth
IBAB said H1 2026 revenue and margin grew, citing robust proton therapy orders and reaffirmed guidance.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.